: Mal! 1
JUN 1.5 2008 Kodoul) Led
Reliant Technologies, Inc.
Reliant Laser System II
510(k) Premarket Notification
510(k) SUMMARY
As required by Section 12 of the Medical Devices Act of 1990, Reliant technologies, Inc.
is providing a summary of safety and effectiveness information available for Reliant
Technologies, Inc. Laser System, as well as the substantial equivalence decision making
process.
Submitter: Reliant Technologies, Inc.
Address: 260 Sheridan Ave.
Suite 309
Palo Alto, CA 94306
Contact Person: Heather Tanner
Clinical and Regulatory Affairs
Telephone: (650) 473-0200 ext. 103
Facsimile: (650) 473-0357
Date prepared: March 5, 2004
Device Trade Name: Reliant Laser System II
Common Name: Dermatology Laser
Classification Name: Laser Surgical Instrument
21 C.F.R § 878.4810
Legally Marketed Predicate Devices: -Reliant Laser System K031795
-Altus Medical CoolGuide Lasers w/Pulsed
Light Handpiece K023954
-Aramis II Dermatological Laser K023734
-Candela Smoothbeam Laser System
K030846
-Candela YAG Family of Lasers
K033172
-Lumenis Ultrapulse Encore Laser,
K022060
Description of the Reliant Laser System II:
The Reliant Laser System II consists of a set of fiber lasers, controlled by an embedded
processor, to be used in dermatology. The laser system uses scanning and focusing optics
to deliver a pattern of thermal energy to the epidermis and upper dermis. Device
accessories include tip attachments and pre-treatment solution.

KHOU) 2a >
Indications for use of Reliant Laser System II:
The Reliant Laser System II is intended for:
Dermatological procedures requiring the coagulation of soft tissue;
Treatment of periorbital wrinkles;
Photocoagulation of pigmented lesions, such as, but not limited to lentigos (age
spots), solar lentigos (sun spots) and dyschromia.
Performance Standards:
Asa laser product, the Reliant Laser System Il is required to conform and does conform
to the Laser Performance Standard (21 CFR).
SUBSTANTIAL EQUIVALENCE COMPARISON
The technological characteristics and indications for use of the Reliant Laser System II
are similar to those of the cited predicate laser devices. These devices are equivalent in
terms of design, materials, principal of operation, and product specifications. Any
differences between the Reliant Technologies Laser System II and the predicate devices
do not raise new issues regarding safety or effectiveness.
Clinical Performance Data
Results of clinical evaluations were used to demonstrate that the Reliant Technologies
Laser System II functioned as clinically intended. Sufficient data have been gathered
from clinical studies to determine that the Reliant Laser System II performs as clinically
intended and that no new issues of safety and effectiveness are introduced.
CONCLUSION
Based on the design, materials, function, intended use, and clinical evaluation, the Reliant
Technologies Laser System II is substantially equivalent to the devices currently
marketed under the Federal Food, Drug and Cosmetic Act. In addition, the Reliant
Technologies Laser System II raises no new safety or effectiveness issues. Therefore,
safety and effectiveness are reasonably assured, justifying 510(k) clearance for
commercial sale.

gems
i DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
(Qe
Food and Drug Administration
JUN 15 2008 Roseville MD 20650."
Ms. Heather Tanner
Clinical and Regulatory Affairs
Reliant Technologies, Inc.
260 Sheridan Avenue, Suite 309
Palo Alto, California 94306
Re: K040617
Trade/Device Name: Reliant Laser System II
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: May 5, 2004
Received: May 6, 2004
Dear Ms. Tanner:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencics. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CER Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Ms. Heather Tanner
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
“Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www. fda.gov/cdrh/dsma/dsmamain. html

Sincerely yours,

Twwane €. Varveat
‘celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health
Enclosure

Indications for Use
510(k) Number (if known): K040617
Device Name: Reliant Technologies Laser System "
Indications For Use:
The Reliant Technologies Laser System Il is intended for:
-Dermatological procedures requiring the coagulation of soft tissue;
-Treatment of periorbital wrinkles;
-Photocoagulation of pigmented lesions, such as, but not limited to lentigos (age
spots), solar lentigos (sun spots) and dyschromia.
Prescription Use ___X__ AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)
an
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Wivision Sign-Off) —_
Division of General, Restorative,
and Neurological Devices Page 1 of
510(k) Number_/ 670 6/

